top of page

About the C-BEYOND Study

The C-BEYOND Study is comparing the safety and effectiveness of an investigational drug (study drug) with another drug (comparator drug). The comparator drug is a generic version of a drug approved in the United States and Canada to treat HCV, but this generic version being used in the study has only been approved in the United States. The study drug is investigational, and it is not approved for the treatment of HCV infection.


Up to 830 people will take part in this study.

C-BEYOND Study Logo REDO Resize 2.png

What will happen in the study?

While current HCV treatments work, they may not be suitable for all patients with HCV. If you take part, you will be in the C-BEYOND Study for about 9.5 months. You will need to:

  • Visit the study center up to 10 times for tests and assessments, and

  • Take the study drug or comparator drug by mouth every day for 8 or 12 weeks.

  ​

THE STUDY IS MADE UP OF 3 PARTS:

Who can take part?

You, or someone you care for, may be able to take part if you/they:​​​

​​

  • Are 18 to 85 years of age

  • Have chronic HCV infection

  • Do not have a hepatitis B virus (HBV) infection

​​

​Other criteria apply.

bottom of page